2017•BloodRequires access

How Do Carriers of Haemophilia with Clotting Factor Deficiency Compare with Mild Male Haemophilia Patients

Simona Raso, Lambert Catherine, N. Lannoy, Cedric R.J.R. Hermans

Open publisher page 0 citations

Abstract

Introduction Because of the recessive X-linked inheritance pattern of haemophilia, men are mainly affected while women are more commonly heterozygote carriers of the disease. Carriers of haemophilia may exhibit an increased bleeding tendency depending on to their clotting factors. However female haemophilia as a disease entity has so far received much less attention than haemophilia in males. In this study we compared the clotting factor levels, clinical presentation and treatment modalities among carriers with clotting factor deficiency referred as female haemophilia patients and mild male haemophilia patients. Methods All male patients with mild HA or HB and identified haemophilia carriers with a clotting factor deficiency in the mild range (FVIII or FIX levels 0.05-0.5 IU/mL) regularly followed at the Cliniques universitaires Saint-Luc, Brussels were enrolled in the study. The following parameters were recorded: basal level of the deficient factor, age, trigger for diagnosis, age at diagnosis, bleeding phenotype, response to desmopressin (DDAVP). Hemorrhagic phenotype was evaluated taking in consideration 12 different typical bleeding symptoms. Results 44 carriers (32 carrying HA and 12 HB) and 77 male patients (55 with HA and 12 with HB) were identified compared. Carriers had significantly higher clotting factors levels than male patients (0.33 IU/ml vs. 0.20 IU/ml, p menorrhagia was the most frequent symptom (64%) and postpartum hemorrhages was reported in 34% of pregnancies. When these two feminine items were removed from the comparison, the most prevalent bleeding symptoms in both male and female patients were as follows: mucocutaneous bleeding (81% men vs 77% women), bleeding post medical interventions (69% vs 50%) and hematoma (68% vs 34%). Joint bleeds were reported by only 4% of carriers and by 36% of male patients. DDAVP test infusion was performed in the majority of male patients with HA (75%) with an overall response rate (ORR) of 92% (73% CR and 18% PR). In the group of carriers the test was performed in 66% with ORR of 95% (90% CR and 5%PR). Conclusions Carriers of haemophilia with clotting factor deficiency referred to as female haemophilia patients represent one third (36%; 44/121) of the whole population with mild haemophilia. Even if female patients are diagnosed later than male patients and the main trigger for the diagnosis was the family screening rather than bleeding symptoms, we found a comparable bleeding phenotype, characterized by mucocutaneous and post injuries bleeding complications. Menstruations and pregnancy represent an intrinsic hemostatic challenge and influence the management of female carriers. Carriers with clotting factor levels in the range of mild haemophilia represent a significant group of patients and should be considered and managed as female haemophilia patients requiring appropriate management and associated with specific challenges that deserve more research. Disclosures No relevant conflicts of interest to declare.

About this research paper

What this paper is about

Introduction Because of the recessive X-linked inheritance pattern of haemophilia, men are mainly affected while women are more commonly heterozygote carriers of the disease. Carriers of haemophilia may exhibit an increased bleeding tendency depending on to their clotting factors. However female haemophilia as a disease entity has so far received much less attention than haemophilia in males. In this study we compared the clotting factor levels, clinical presentation and treatment modalities among carriers with clotting factor deficiency referred as female haemophilia patients and mild male haemophilia patients. Methods All male patients with mild HA or HB and identified haemophilia carriers with a clotting factor deficiency in the mild range (FVIII or FIX levels 0.05-0.5 IU/mL) regularly followed at the Cliniques universitaires Saint-Luc, Brussels were enrolled in the study. The following parameters were recorded: basal level of the deficient factor, age, trigger for diagnosis, age at diagnosis, bleeding phenotype, response to desmopressin (DDAVP). Hemorrhagic phenotype was evaluated taking in consideration 12 different typical bleeding symptoms. Results 44 carriers (32 carrying HA and 12 HB) and 77 male patients (55 with HA and 12 with HB) were identified compared. Carriers had significantly higher clotting factors levels than male patients (0.33 IU/ml vs. 0.20 IU/ml, p menorrhagia was the most frequent symptom (64%) and postpartum hemorrhages was reported in 34% of pregnancies. When these two feminine items were removed from the comparison, the most prevalent bleeding symptoms in both male and female patients were as follows: mucocutaneous bleeding (81% men vs 77% women), bleeding post medical interventions (69% vs 50%) and hematoma (68% vs 34%). Joint bleeds were reported by only 4% of carriers and by 36% of male patients. DDAVP test infusion was performed in the majority of male patients with HA (75%) with an overall response rate (ORR) of 92% (73% CR and 18% PR). In the group of carriers the test was performed in 66% with ORR of 95% (90% CR and 5%PR). Conclusions Carriers of haemophilia with clotting factor deficiency referred to as female haemophilia patients represent one third (36%; 44/121) of the whole population with mild haemophilia. Even if female patients are diagnosed later than male patients and the main trigger for the diagnosis was the family screening rather than bleeding symptoms, we found a comparable bleeding phenotype, characterized by mucocutaneous and post injuries bleeding complications. Menstruations and pregnancy represent an intrinsic hemostatic challenge and influence the management of female carriers. Carriers with clotting factor levels in the range of mild haemophilia represent a significant group of patients and should be considered and managed as female haemophilia patients requiring appropriate management and associated with specific challenges that deserve more research. Disclosures No relevant conflicts of interest to declare.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction Because of the recessive X-linked inheritance pattern of haemophilia, men are mainly affected while women are more commonly heterozygote carriers of the disease. Carriers of haemophilia may exhibit an increased bleeding tendency depending on to their clotting factors. However female haemophilia as a disease entity has so far received much less attention than haemophilia in males. In this study we compared the clotting factor levels, clinical presentation and treatment modalities among carriers with clotting factor deficiency referred as female haemophilia patients and mild male haemophilia patients. Methods All male patients with mild HA or HB and identified haemophilia carriers with a clotting factor deficiency in the mild range (FVIII or FIX levels 0.05-0.5 IU/mL) regularly followed at the Cliniques universitaires Saint-Luc, Brussels were enrolled in the study. The following parameters were recorded: basal level of the deficient factor, age, trigger for diagnosis, age at diagnosis, bleeding phenotype, response to desmopressin (DDAVP). Hemorrhagic phenotype was evaluated taking in consideration 12 different typical bleeding symptoms. Results 44 carriers (32 carrying HA and 12 HB) and 77 male patients (55 with HA and 12 with HB) were identified compared. Carriers had significantly higher clotting factors levels than male patients (0.33 IU/ml vs. 0.20 IU/ml, p menorrhagia was the most frequent symptom (64%) and postpartum hemorrhages was reported in 34% of pregnancies. When these two feminine items were removed from the comparison, the most prevalent bleeding symptoms in both male and female patients were as follows: mucocutaneous bleeding (81% men vs 77% women), bleeding post medical interventions (69% vs 50%) and hematoma (68% vs 34%). Joint bleeds were reported by only 4% of carriers and by 36% of male patients. DDAVP test infusion was performed in the majority of male patients with HA (75%) with an overall response rate (ORR) of 92% (73% CR and 18% PR). In the group of carriers the test was performed in 66% with ORR of 95% (90% CR and 5%PR). Conclusions Carriers of haemophilia with clotting factor deficiency referred to as female haemophilia patients represent one third (36%; 44/121) of the whole population with mild haemophilia. Even if female patients are diagnosed later than male patients and the main trigger for the diagnosis was the family screening rather than bleeding symptoms, we found a comparable bleeding phenotype, characterized by mucocutaneous and post injuries bleeding complications. Menstruations and pregnancy represent an intrinsic hemostatic challenge and influence the management of female carriers. Carriers with clotting factor levels in the range of mild haemophilia represent a significant group of patients and should be considered and managed as female haemophilia patients requiring appropriate management and associated with specific challenges that deserve more research. Disclosures No relevant conflicts of interest to declare.

Key concepts: Haemophilia, Medicine, Clotting factor, Haemophilia A, Coagulopathy, Mucocutaneous zone, Internal medicine, Gastroenterology

Related papers

Back to paper searchBrowse research topicsOriginal source
How Do Carriers of Haemophilia with Clotting Factor Deficiency Compare with Mild Male Haemophilia Patients — Research Paper | ScholarLens